Business Description
Venus Medtech (Hangzhou) Inc
ISIN : CNE100003PJ8
Share Class Description:
HKSE:02500: Class HCompare
Compare
Traded in other countries / regions
02500.Hong KongVMTHF.USA IPO Date
2019-12-10Description
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically majority of the revenue is derived from Mainland China.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.98 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -1.2 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -0.18 | |||||
| Beneish M-Score | -2.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.3 | |||||
| 3-Year EBITDA Growth Rate | -47.9 | |||||
| 3-Year EPS without NRI Growth Rate | -47.8 | |||||
| 3-Year FCF Growth Rate | -27.7 | |||||
| 3-Year Book Growth Rate | -12.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.22 | |||||
| Quick Ratio | 1.97 | |||||
| Cash Ratio | 0.98 | |||||
| Days Inventory | 446.75 | |||||
| Days Sales Outstanding | 252.62 | |||||
| Days Payable | 124.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | 10.48 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.26 | |||||
| Operating Margin % | -96.19 | |||||
| Net Margin % | -120.3 | |||||
| FCF Margin % | -105.01 | |||||
| ROE % | -18.74 | |||||
| ROA % | -12.61 | |||||
| ROIC % | -13.67 | |||||
| ROC (Joel Greenblatt) % | -61.94 | |||||
| ROCE % | -14.15 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.86 | |||||
| PB Ratio | 0.84 | |||||
| Price-to-Tangible-Book | 1.98 | |||||
| EV-to-EBIT | -4.26 | |||||
| EV-to-Forward-EBIT | -9.26 | |||||
| EV-to-EBITDA | -5.58 | |||||
| EV-to-Forward-EBITDA | -23.32 | |||||
| EV-to-Revenue | 4.91 | |||||
| EV-to-Forward-Revenue | 1.85 | |||||
| EV-to-FCF | -4.68 | |||||
| Earnings Yield (Greenblatt) % | -23.47 | |||||
| FCF Yield % | -21.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Venus Medtech (Hangzhou) Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 506.253 | ||
| EPS (TTM) (HK$) | -1.392 | ||
| Beta | 1.08 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (HK$) | 0 | ||
| 20-Day SMA (HK$) | 5.62 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (HK$) | 5.62 - 5.62 | ||
| Shares Outstanding (Mil) | 441.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Venus Medtech (Hangzhou) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Venus Medtech (Hangzhou) Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Venus Medtech (Hangzhou) Inc Frequently Asked Questions
What is Venus Medtech (Hangzhou) Inc(HKSE:02500)'s stock price today?
The current price of HKSE:02500 is HK$5.62. The 52 week high of HKSE:02500 is HK$5.62 and 52 week low is HK$5.62.
When is next earnings date of Venus Medtech (Hangzhou) Inc(HKSE:02500)?
The next earnings date of Venus Medtech (Hangzhou) Inc(HKSE:02500) is .
Does Venus Medtech (Hangzhou) Inc(HKSE:02500) pay dividends? If so, how much?
Venus Medtech (Hangzhou) Inc(HKSE:02500) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers